Trial Profile
A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms OVINTRA
- 10 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 16 Nov 2010 New trial record